PDF herunterladen
Dtsch Med Wochenschr 2005; 130(17): 1097-1102
DOI: 10.1055/s-2005-866794
Übersichten
Diabetologie / Psychiatrie
© Georg Thieme Verlag Stuttgart · New York

Diabetes und Depression

Diabetes and depressionF. Regen1 , A. Merkl1 , I. Heuser1 , M. Dettling1 , I. Anghelescu1
  • 1Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin; Campus Benjamin Franklin
Weitere Informationen

Publikationsverlauf

eingereicht: 24.1.2005

akzeptiert: 7.4.2005

Publikationsdatum:
19. April 2005 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

In Kohortenstudien wurden eine erhöhte Prävalenz depressiver Störungen bei diabetischen Patienten gezeigt. Trotz zahlreicher Untersuchungen sind die zugrundeliegenden Entstehungsmechanismen bisher nicht vollständig geklärt. Eine Rolle spielen vermutlich eine erhöhte Ausschüttung der am Glukosestoffwechsel beteiligten gegenregulierenden Hormone, Veränderungen des transmembranösen Glukosetransports und eine erhöhte inflammatorische Antwort. Die Diagnosestellung „Depression” bei diabetischen Patienten kann dadurch erschwert sein, dass typische depressive Symptome wie Müdigkeit, Antriebslosigkeit, verminderter Appetit oder sexuelle Funktionsstörungen auch Ausdruck des Diabetes mellitus selbst sein können. Bei der antidepressiven Behandlung ist darauf zu achten, dass es nicht zu einer pharmakogenen Induktion oder zur Verschlechterung einer diabetischen Stoffwechsellage kommt. Selektive Serotoninrückaufnahmehemmer, Venlafaxin und MAO-Inhibitoren scheinen diesbezüglich besonders günstig zu sein. Vorsicht sollte beim Einsatz von atypischen Antipsychotika gelten, da insbesondere Clozapin und Olanzapin, aber auch Quetiapin und Risperidon den Zuckerstoffwechsel negativ beeinflussen können.

Summary

Cohort studies indicate a high prevalence of depression in patients with diabetes mellitus. Despite numerous investigations, the underlying pathophysiologies of the metabolic abnormalities are poorly understood. A possible role play the increased counter-regulatory hormone release involved in glucose homeostasis, alterations in the glucose transport function and increased inflammatory activation triggered by depression. The diagnose of „depression” in diabetic patients might be hampered by similar symptoms of both conditions as fatigue, psychomotor inhibition, reduced appetite or sexual dysfunction. In treating depressive patients with diabetes one should consider potential induction or worsening of diabetes-like metabolic alterations. Selective serotonin-reuptake-inhibitors, venlafaxin and MAO-Inhibitors constitute a beneficial choice. Atypical antipsychotics like clozapine, olanzapine, quetiapine and risperidone should be given with precaution due to potential effects on glucose homeostasis.

Literatur

  • 1 Agelink M W, Baumann B, Sanner D, Kavuk I, Mueck-Weymann M. Komorbidät zwischen kardiovaskulären Erkrankungen and Depressionen.  Dtsch Med Wochenschr. 2004;  129 697-700
    Google Scholar
  • 2 American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes.  Diabetes Care. 2004;  27 596-601
    Google Scholar
  • 3 Anderson R J, Freedland K E, Clouse R E, Lustman P J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis.  Diabetes Care. 2001;  24 1069-1078
    Google Scholar
  • 4 Bech P, Gudex C, Johansen K S. The WHO (Ten) Well-Being Index: validation in diabetes.  Psychother Psychosom. 1996;  65 183-190
    Google Scholar
  • 5 Chen J L, Spinowitz N, Karwa M. Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report.  Pharmacotherapy. 2003;  23 940-944
    Google Scholar
  • 6 Ciechanowski P S, Katon W J, Russo J E. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs.  Arch Intern Med. 2000;  160 3278-3285
    Google Scholar
  • 7 Clouse R E, Lustman P J, Freedland K E, Griffith L S, McGill J B, Carney R M. Depression and coronary heart disease in women with diabetes.  Psychosom Med. 2003;  65 376-383
    Google Scholar
  • 8 de Groot M, Anderson R, Freedland K E, Clouse R E, Lustman P J. Association of depression and diabetes complications: a meta-analysis.  Psychosom Med. 2001;  63 619-630
    Google Scholar
  • 9 DiMatteo M R, Lepper H S, Croghan T W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence.  Arch Intern Med. 2000;  160 2101-2107
    Google Scholar
  • 10 Eaton W W, Armenian H, Gallo J, Pratt L, Ford D E. Depression and risk for onset of type II diabetes. A prospective population-based study.  Diabetes Care. 1996;  19 1097-1102
    Google Scholar
  • 11 Egede L E, Zheng D. Independent factors associated with major depressive disorder in a national sample of individuals with diabetes.  Diabetes Care. 2003;  26 104-111
    Google Scholar
  • 12 Egede L E. Diabetes, major depression, and functional disability among U.S. adults.  Diabetes Care. 2004;  27 421-428
    Google Scholar
  • 13 Egede L E. Effects of depression on work loss and disability bed days in individuals with diabetes.  Diabetes Care. 2004;  27 1751-1753
    Google Scholar
  • 14 Finkelstein E A, Bray J W, Chen H, Larson M J, Miller K, Tompkins C, Keme A, Manderscheid R. Prevalence and costs of major depression among elderly claimants with diabetes.  Diabetes Care. 2003;  26 415-420
    Google Scholar
  • 15 Fortner M R, Brown K, Varia I M, Gersing K R, O’Connor C, Doraiswamy P M. Effect of Bupropion SR on the quality of life of elderly depressed patients with comorbid medical disorders.  J Clin Psychiatry. 1999;  1 174-179
    Google Scholar
  • 16 Fried S K, Bunkin D A, Greenberg A S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid.  J Clin Endocrinol Metab. 1998;  83 847-850
    Google Scholar
  • 17 Gary T L, Crum R M, Cooper-Patrick L, Ford D, Brancati F L. Depressive symptoms and metabolic control in African-Americans with type 2 diabetes.  Diabetes Care. 2000;  23 23-29
    Google Scholar
  • 18 Gavard J A, Lustman P J, Clouse R E. Prevalence of depression in adults with diabetes. An epidemiological evaluation.  Diabetes Care. 1993;  16 1167-1178
    Google Scholar
  • 19 Ghaeli P, Shahsavand E, Mesbahi M, Kamkar M Z, Sadeghi M, Dashti-Khavidaki S. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder.  J Clin Psychopharmacol. 2004;  24 386-388
    Google Scholar
  • 20 Glassman A H, Helzer J E, Covey L S, Cottler L B, Stetner F, Tipp J E, Johnson J. Smoking, smoking cessation, and major depression.  J Am Med Assoc. 1990;  264 1546-1549
    Google Scholar
  • 21 Glassman A H, O’Connor C M, Califf R M, Swedberg K, Schwartz P, Bigger J T, Krishnan K R, van Zyl L T, Swenson J R, Finkel M S, Landau C, Shapiro P A, Pepine C J, Mardekian J, Harrison W M, Barton D, Mclvor M. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group . Sertraline treatment of major depression in patients with acute MI or unstable angina.  J Am Med Assoc. 2002;  288 701-709
    Google Scholar
  • 22 Golden S H, Williams J E, Ford D E, Yeh H C, Paton Sanford C, Nieto F J, Brancati F L. Atherosclerosis risk in communities study . Depressive symptoms and the risk of type 2 diabetes: the Atherosclerosis Risk in Communities study.  Diabetes Care. 2004;  27 429-435
    Google Scholar
  • 23 Goldney R D, Phillips P J, Fisher L J, Wilson D H. Diabetes, depression, and quality of life: a population study.  Diabetes Care. 2004;  27 1066-1070
    Google Scholar
  • 24 Goodman E, Whitaker R C. A prospective study of the role of depression in the development and persistence of adolescent obesity.  Pediatrics. 2002;  110 497-504
    Google Scholar
  • 25 Henkel V, Mergl R, Coyne J C, Kohnen R, Moller H J, Hegerl U. Screening for depression in primary care: will one or two items suffice?.  Eur Arch Psychiatry Clin Neurosci. 2004;  254 215-223
    Google Scholar
  • 26 Iosifescu D V, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder.  Current Psychiatry Reports. 2004;  6 193-201
    Google Scholar
  • 27 Katon W, von Korff M, Ciechanowski P, Russo J, Lin E, Simon G, Ludman E, Walker E, Bush T, Young B. Behavioral and clinical factors associated with depression among individuals with diabetes.  Diabetes Care. 2004;  27 914-920
    Google Scholar
  • 28 Katon W J, Lin E H, Russo J, Von Korff M, Ciechanowski P, Simon G, Ludman E, Bush T, Young B. Cardiac risk factors in patients with diabetes mellitus and major depression.  J Gen Intern Med. 2004;  19 1192-1199
    Google Scholar
  • 29 Katon W J, Von Korff M, Lin E H, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression.  Arch Gen Psychiatry. 2004;  61 1042-1049
    Google Scholar
  • 30 Kawakami N, Takatsuka N, Shimizu H, Ishibashi H. Depressive symptoms and occurrence of type 2 diabetes among Japanese men.  Diabetes Care. 1999;  22 1071-1076
    Google Scholar
  • 31 Kent S, Bluthe R M, Kelley K W, Dantzer R. Sickness behavior as a new target for drug development.  Trends Pharmacol Sci. 1992;  13 24-28
    Google Scholar
  • 32 Kompetenznetz „Depression”;. http://www.kompetenznetz-depression.de
    Google Scholar
  • 33 Ludman E J, Katon W, Russo J, Von Korff M, Simon G, Ciechanowski P, Lin E, Bush T, Walker E, Young B. Depression and diabetes symptom burden.  Gen Hosp Psychiatry. 2004;  26 430-436
    Google Scholar
  • 34 Lustman P J, Anderson R J, Freedland K E, de Groot M, Carney R M, Clouse R E. Depression and poor glycemic control: a meta-analytic review of the literature.  Diabetes Care. 2000;  23 934-942
    Google Scholar
  • 35 Lustman P J, Clouse R E, Griffith L S, Carney R M, Freedland K E. Screening for depression in diabetes using the Beck Depression Inventory.  Psychosom Med. 1997;  59 24-31
    Google Scholar
  • 36 Lustman P J, Freedland K E, Carney R M, Hong B A, Clouse R E. Similarity of depression in diabetic and psychiatric patients.  Psychosom Med. 1992;  54 602-611
    Google Scholar
  • 37 Lustman P J, Griffith L S, Clouse R E, Freedland K E, Eisen S A, Rubin E H, Carney R M, McGill J B. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial.  Psychosom Med. 1997;  59 241-250
    Google Scholar
  • 38 Lustman P J, Griffith L S, Freedland K E, Clouse R E. The course of major depression in diabetes.  Gen Hosp Psychiatry. 1997;  19 138-143
    Google Scholar
  • 39 Lustman P J, Griffith L S, Freedland K E, Kissel S S, Clouse R E. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial.  Ann Intern Med. 1998;  12 613-621
    Google Scholar
  • 40 Lustman P J, Harper G W. Nonpsychiatric physicians’ identification and treatment of depression in patients with diabetes.  Compr Psychiatry. 1987;  28 22-27
    Google Scholar
  • 41 Miller G E, Stetler C A, Carney R M, Freedland K E, Banks W A. Clinical depression and inflammatory risk markers for coronary heart disease.  Am J Cardiol. 2002;  90 1279-1283
    Google Scholar
  • 42 Musselman D L, Betan E, Larsen H, Phillips L S. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment.  Biol Psychiatry. 2003;  54 317-329
    Google Scholar
  • 43 Musselman D L, DiBattista C, Nathan K I, Kilts C D, Schatzberg A F, Nemeroff C B. Biology of mood disorders. 2nd ed Washington, DC:APA Press In: Schatzberg AF, Nemeroff CB, editors. American Psychiatric Textbook of Psychopharmacology 1998: 550-588
    Google Scholar
  • 44 Newcomer J W, Haupt D W, Fucetola R, Melson A K, Schweiger J A, Cooper B P, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.  Arch Gen Psychiatry. 2002;  59 337-345
    Google Scholar
  • 45 Niedermaier N, Bohrer E, Schulte K, Schlattmann P, Heuser I. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke.  J Clin Psychiatry. 2004;  65 1619-1623
    Google Scholar
  • 46 Ormel J, Rijsdijk F V, Sullivan M, van Sonderen E, Kempen G I. Temporal and reciprocal relationship between IADL/ADL disability and depressive symptoms in late life.  J Gerontol B Psychol Sci Soc Sci. 2002;  57 338-347
    Google Scholar
  • 47 Ross R. Atherosclerosis - an inflammatory disease.  N Engl J Med. 1999;  340 115-126
    Google Scholar
  • 48 Schindler F, Anghelescu I. HAMD-Subskalen: schneller und besser als die Langversion?.  Neurotransmitter. 2004;  15 56-58
    Google Scholar
  • 49 Weber-Hamann B, Hentschel F, Kniest A, Deuschle M, Colla M, Lederbogen F, Heuser I. Hypercortisolemic depression is associated with increased intra-abdominal fat.  Psychosom Med. 2002;  64 274-277
    Google Scholar
  • 50 Weyerer S, Hewer W, Pfeifer-Kurda M, Dilling H. Psychiatric disorders and diabetes - results from a community study.  J Psychosom Res. 1989;  33 633-640
    Google Scholar
  • 51 Williams J W, Katon W, Lin E H, Noel P H, Worchel J, Cornell J, Harpole L, Fultz B A, Hunkeler E, Mika V S, Unutzer J. IMPACT Investigators . The effectiveness of depression care management on diabetes-related outcomes in older patients.  Ann Intern Med. 2004;  140 1015-1024
    Google Scholar
  • 52 Wilson W H, Bigelow D A. The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs.  J clin Psychopharmacol. 2004;  24 452-454
    Google Scholar

Francesca Regen

Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin

Eschenallee 3

14050 Berlin

Telefon: 030/8445 8351

Fax: 030/8445 8365

eMail: francesca.regen@charite.de

      >